Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,03€(+117,84%). Der Median liegt bei 4,03€(+117,84%).
Kaufen | 5 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to purchase additional shares of common stock and/or accompanying warrants. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $45.0 million.» Mehr auf globenewswire.com
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants to purchase up to an additional 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) in connection with the public offering.» Mehr auf globenewswire.com
Achieve Life Sciences Announces Proposed Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof) offered in the public offering.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −11,86 Mio | 97,05% |
EBITDA | 0,00 | 100,00% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 64,19 Mio€ |
Anzahl Aktien | 34,69 Mio |
52 Wochen-Hoch/Tief | 4,51€ - 1,56€ |
Dividenden | Nein |
Beta | 1,64 |
KGV (PE Ratio) | −1,64 |
KGWV (PEG Ratio) | 0,19 |
KBV (PB Ratio) | 7,36 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Achieve Life Sciences, Inc. ist ein pharmazeutisches Unternehmen im klinischen Stadium, das Cytisiniclin für die Raucherentwöhnung und Nikotinsucht in Kanada, den Vereinigten Staaten und Großbritannien entwickelt und vermarktet. Das Unternehmen bietet Cytisinicline an, ein pflanzliches Alkaloid, das mit Nikotinrezeptoren im Gehirn interagiert und so die Schwere der Nikotinentzugssymptome verringert. Es hat Lizenzvereinbarungen mit Sopharma AD und der Universität von Bristol. Das Unternehmen hat seinen Sitz in Vancouver, Kanada.
Name | Achieve Life Sciences |
CEO | Richard A. B. Stewart |
Sitz | Vancouver, bc USA |
Website | |
Industrie | Gesundheitswesen: Ausstattung und Produkte |
Börsengang | |
Mitarbeiter | 25 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ACHV |
Frankfurt | SP4P.F |
Düsseldorf | SP4P.DU |
München | SP4P.MU |
Assets entdecken
Shareholder von Achieve Life Sciences investieren auch in folgende Assets